论文部分内容阅读
Aim: Butyrylcholinesterases (BuChE, EC 3.1.1.8) is emerging as an important pharmacological target in Alzheimers disease (AD) therapy.Due to high cost and laboriousness in experimental tests, it is necessary to develop robust in silico methods to predict the activity of BuChE inhibitors.In order to distinguish BuChE inhibitors (BuChEIs) and non-inhibitors, several classification models (SVM models and naive Bayesian models) were built.